FRAT2 Inhibitors

FRAT2 inhibitors refer to a group of chemicals that indirectly influence the activity of the FRAT2 protein by targeting the Wnt/β-catenin signaling pathway. These inhibitors operate through various mechanisms to modulate the pathway's activity, which FRAT2 is known to promote. Quercetin and Lithium Chloride, for example, inhibit GSK-3β, a kinase that phosphorylates and targets β-catenin for proteasomal degradation. Inhibition of GSK-3β stabilizes β-catenin, leading to increased Wnt signaling, which is typically enhanced by FRAT2. Therefore, these inhibitors indirectly alter the signaling outcome that FRAT2 would otherwise facilitate. In contrast, XAV-939 and JW55 act on the destruction complex of the Wnt pathway, which includes proteins such as Axin. By inhibiting tankyrase enzymes, these compounds stabilize Axin, which promotes the degradation of β-catenin and consequently decreases Wnt signal transduction. This reduction in Wnt signaling would oppose the promoting effect of FRAT2. Similarly, other compounds like LGK-974 inhibit the enzyme Porcupine, which is responsible for Wnt ligand secretion. By reducing the availability of Wnt ligands, these inhibitors dampen the pathway's activity. The small molecule inhibitors CGP049090 and PKF118-310 interfere with the transcription machinery of the Wnt pathway by disrupting the interaction between β-catenin and TCF, thereby affecting the transcription of Wnt target genes. Salinomycin and Pyrvinium Pamoate employ different strategies to modulate Wnt signaling, with Salinomycin targeting cancer stem cells and Pyrvinium Pamoate activating CK1α, leading to β-catenin degradation. Lastly, KY02111 targets the Wnt co-receptor LRP6, disrupting its interaction and further promoting β-catenin degradation. These chemicals, through their distinct mechanisms, contribute to a collective dampening of the Wnt/β-catenin signaling pathway, to which FRAT2 is implicated. By interfering with various nodes of this pathway, they indirectly influence FRAT2's role within the cell.